down arrow

ESSA Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA29668H7085
USD
0.20
0.00 (0.00%)

Oct 10

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.185.76
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

20.34%

Held by 15 FIIs

DII

73.91%

Held by 5 DIIs

Promoter

5.67%

How big is ESSA Pharma, Inc.?

22-Jun-2025

As of Jun 18, ESSA Pharma, Inc. has a market capitalization of 75.02 million and reported net sales of 0.00 million with a net profit of -28.49 million for the latest four quarters. As of Sep 24, the company has shareholder's funds of 124.61 million and total assets of 128.11 million.

As of Jun 18, ESSA Pharma, Inc. has a market capitalization of 75.02 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company's net sales for the latest four quarters are 0.00 million, and the consolidated net profit for the same period is -28.49 million.<BR><BR>As of Sep 24, the reporting period shows shareholder's funds of 124.61 million and total assets of 128.11 million.

Read More

What does ESSA Pharma, Inc. do?

22-Jun-2025

ESSA Pharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $6 million and a market cap of $75.02 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -25.10%.

Overview: <BR>ESSA Pharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 75.02 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -25.10% <BR>Price to Book: 0.66 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is ESSA Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, ESSA Pharma, Inc. is in a bearish trend with weak strength, indicated by bearish MACD readings and moving averages, despite a bullish RSI, and has significantly underperformed the S&P 500 with a 1-year return of -96.53%.

As of 2 September 2025, the technical trend for ESSA Pharma, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by bearish MACD readings on both weekly and monthly time frames, along with bearish moving averages on the daily chart. The Bollinger Bands show a mildly bearish trend weekly and bearish monthly, while the KST and OBV are also bearish across both time frames. Although the RSI is bullish on both weekly and monthly charts, it is overshadowed by the overall bearish indicators. <BR><BR>In terms of performance, ESSA Pharma has significantly underperformed compared to the S&P 500, with a 1-year return of -96.53% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-23.07%

stock-summary
Price to Book

0.10

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-88.5%
0%
-88.5%
6 Months
-86.76%
0%
-86.76%
1 Year
-96.47%
0%
-96.47%
2 Years
-93.09%
0%
-93.09%
3 Years
-87.5%
0%
-87.5%
4 Years
-97.42%
0%
-97.42%
5 Years
-96.76%
0%
-96.76%

ESSA Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is ESSA Pharma, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for ESSA Pharma, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by bearish MACD readings on both weekly and monthly time frames, along with bearish moving averages on the daily chart. The Bollinger Bands show a mildly bearish trend weekly and bearish monthly, while the KST and OBV are also bearish across both time frames. Although the RSI is bullish on both weekly and monthly charts, it is overshadowed by the overall bearish indicators. In terms of performance, ESSA Pharma has significantly underperformed compared to the S&P 500, with a 1-year return of -96.53% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-7.62%
EBIT to Interest (avg)
-33.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.67
EV to EBIT
1.13
EV to EBITDA
1.14
EV to Capital Employed
37.84
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3339.95%
ROE (Latest)
-25.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.08%)

Foreign Institutions

Held by 15 Foreign Institutions (20.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 44.44% vs 1.37% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-8.60",
          "chgp": "43.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.00",
          "val2": "-7.20",
          "chgp": "44.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is -7.14% vs 24.22% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-34.30",
          "val2": "-32.00",
          "chgp": "-7.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.50",
          "val2": "-26.60",
          "chgp": "-7.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.90
-8.60
43.02%
Interest
0.00
0.00
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-4.00
-7.20
44.44%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 44.44% vs 1.37% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-34.30
-32.00
-7.19%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-28.50
-26.60
-7.14%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is -7.14% vs 24.22% in Sep 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About ESSA Pharma, Inc. stock-summary
stock-summary
ESSA Pharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."